1.21Hydroxyzine vs Buspirone for GAD

Quality assessmentSummary of findingsImportance
No of patientsEffectQuality
No of studiesDesignLimitationsInconsistencyIndirectnessImprecisionOther considerationsHydroxyzineBuspironeRelative (95% CI)Absolute
HAM-A (Better indicated by lower values)
1randomised trialsno serious limitationsno serious inconsistencyno serious indirectnessserious1none8182-SMD 0.26 lower (0.57 lower to 0.05 higher)[plus sign in circle][plus sign in circle][plus sign in circle]
MODERATE
At least one side effect
1randomised trialsno serious limitationsno serious inconsistencyno serious indirectnessserious2none32/81 (39.5%)31/82 (37.8%)RR 1.05 (0.71 to 1.54)19 more per 1000 (from 110 fewer to 204 more)[plus sign in circle][plus sign in circle][plus sign in circle]
MODERATE
1

Confidence intervals compatible with benefit for hydroxyzine or no difference

2

Confidence intervals compatible with benefit for either intervention

Confidence intervals compatible with benefit for hydroxyzine or no difference

Confidence intervals compatible with benefit for either intervention

From: Appendix 18, GRADE evidence profiles

Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.